August 06, 2019

Moving Past Actavis with Evolving Lifecycle Management Strategies

配信申込

ジャンプリンクテキスト

 

For nearly two decades, reverse payments have been the perennial focus in the pharmaceutical industry and among antitrust professionals. But while courts continue to grapple with the implications of the Supreme Court’s decision in FTC v. Actavis, Inc., 570 U.S. 136 (2013), more attention is being brought to pharmaceutical companies’ lifecycle management strategies.

Read this chapter in Shearman & Sterling’s 2019 Antitrust Annual Report, “Moving Past Actavis with Evolving Lifecycle Management Strategies”

著者等

Jessica K. Delbaum

パートナー

独占禁止法

+1 212 848 4815

+1 212 848 4815

ニューヨーク